Clin Neuropathol. 2020 Jul/Aug;39(4):188-195. doi: 10.5414/NP301228.
This study aimed to investigate the survival and prognostic factors for anaplastic glioma, and whether the updated 2016 WHO classification had superior ability to predict survival.
Between January 2001 and December 2013, 113 consecutive patients were diagnosed with anaplastic glioma based on the 2007 WHO classification. We re-classified their diagnoses in accordance with the 2016 WHO classification. The Kaplan-Meier method, multivariate Cox proportional regression analysis, and a time-dependent receiver operating characteristic curve were used for the analysis.
The median overall survival was 48.4 months among all patients, and 21.5 months for the (AAw) group. The median progression-free survival was 31.8 months among all patients and 16.4 in the AAw group. Age, promoter methylation status, deep tumor location, and resection extent were associated with overall survival and progression-free survival.
We found that the 2016 WHO classification of central nervous system tumors had superior ability to predict survival in cases of anaplastic glioma, as compared to the 2007 WHO classification.
本研究旨在探讨间变性神经胶质瘤的生存和预后因素，以及新版 2016 年世界卫生组织（WHO）分类是否具有更好的生存预测能力。
2001 年 1 月至 2013 年 12 月期间，根据 2007 年 WHO 分类标准，连续诊断了 113 例间变性神经胶质瘤患者。我们按照 2016 年 WHO 分类标准重新对他们的诊断进行分类。采用 Kaplan-Meier 法、多因素 Cox 比例风险回归分析和时间依赖性受试者工作特征曲线进行分析。
所有患者的中位总生存期为 48.4 个月，AAw 组为 21.5 个月。所有患者的中位无进展生存期为 31.8 个月，AAw 组为 16.4 个月。年龄、MGMT 启动子甲基化状态、肿瘤深部位置和切除程度与总生存期和无进展生存期相关。
与 2007 年 WHO 分类相比，我们发现新版 2016 年中枢神经系统肿瘤 WHO 分类在预测间变性神经胶质瘤的生存方面具有更好的能力。
